Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Galderma's Nemluvio Shows Sustained Benefits In Inflammatory Skin Diseases Through 3 Years

(RTTNews) - Thursday, Galderma (GALD.SW) presented new three-year data from the ARCADIA long-term extension study showing sustained improvements with Nemluvio (nemolizumab) in patients with atopic dermatitis (AD).

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Health & Medicine

More from Thursday 8 October →